NovoCure (NVCR) had its "neutral" rating reaffirmed by Wedbush. They now have a $18.00 price target on the stock.
Gliosarcoma Market Intelligence Report 2026-2030 & 2035: Expansion of Molecular Testing and Increased Research Funding is Driving Industry Growth [Yahoo! Finance]
Novocure to Report First Quarter 2026 Financial Results
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer